Patents by Inventor Franck Lepifre

Franck Lepifre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10316056
    Abstract: Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity. Also, a method of improving muscle quality in obese mammals and treating and/or preventing of obesity and associated complications and/or pathologies, advantageously type 2 diabetes and metabolic syndrome, using the chemical compounds.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: June 11, 2019
    Assignees: BIOPHYTIS, SORBONNE UNVERSITÉ
    Inventors: René Lafont, Waly Dioh, Sophie Raynal, Stanislas Veillet, Franck Lepifre, Jean-Denis Durand
  • Publication number: 20180327444
    Abstract: Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity. Also, a method of improving muscle quality in obese mammals and treating and/or preventing of obesity and associated complications and/or pathologies, advantageously type 2 diabetes and metabolic syndrome, using the chemical compounds.
    Type: Application
    Filed: April 9, 2018
    Publication date: November 15, 2018
    Inventors: RENÉ LAFONT, WALY DIOH, SOPHIE RAYNAL, STANISLAS VEILLET, FRANCK LEPIFRE, JEAN-DENIS DURAND
  • Patent number: 9938315
    Abstract: Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity. Also, a method of improving muscle quality in obese mammals and treating and/or preventing of obesity and associated complications and/or pathologies, advantageously type 2 diabetes and metabolic syndrome, using the chemical compounds.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: April 10, 2018
    Assignees: BIOPHYTIS, UNIVERSITÉ PARIS 6 PIERRE ET MARIE CURIE
    Inventors: René Lafont, Waly Dioh, Sophie Raynal, Stanislas Veillet, Franck Lepifre, Jean-Denis Durand
  • Publication number: 20170226151
    Abstract: Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity. Also, a method of improving muscle quality in obese mammals and treating and/or preventing of obesity and associated complications and/or pathologies, advantageously type 2 diabetes and metabolic syndrome, using the chemical compounds.
    Type: Application
    Filed: May 20, 2015
    Publication date: August 10, 2017
    Inventors: RENÉ LAFONT, WALY DIOH, SOPHIE RAYNAL, STANISLAS VEILLET, FRANCK LEPIFRE, JEAN-DENIS DURAND
  • Patent number: 9365584
    Abstract: The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, inflammation, cancer and cardiovascular diseases.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: June 14, 2016
    Assignee: Poxel
    Inventors: Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze, Franck Lepifre, Laurent Faveriel, Jean-Denis Durand, Christine Charon
  • Patent number: 9284329
    Abstract: Activators of AMPK and therapeutic uses thereof The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, liver disease, hepatic steatosis, non alcoholic fatty liver disease (NAFLD), non alcoholic steato-hepatitis (NASH), liver fibrosis, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, inflammation, cancer, cardiovascular diseases, atherosclerosis, high blood pressure, retinopathies or neuropathies.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: March 15, 2016
    Assignee: POXEL
    Inventors: Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze, Franck Lepifre, Laurent Faveriel, Jean-Denis Durand, Christine Charon
  • Publication number: 20150166566
    Abstract: Activators of AMPK and therapeutic uses thereof The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, liver disease, hepatic steatosis, non alcoholic fatty liver disease (NAFLD), non alcoholic steato-hepatitis (NASH), liver fibrosis, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, inflammation, cancer, cardiovascular diseases, atherosclerosis, high blood pressure, retinopathies or neuropathies.
    Type: Application
    Filed: June 28, 2013
    Publication date: June 18, 2015
    Inventors: Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze, Franck Lepifre, Laurent Faveriel, Jean-Denis Durand, Christine Charon
  • Patent number: 8822475
    Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: September 2, 2014
    Assignee: Critical Outcome Technologies, Inc.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Patent number: 8674097
    Abstract: The present invention relates to compounds of formula (I) wherein X, Y, Z, R1, R2, R3 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diabetes, metabolic syndrome, obesity, cancer, inflammation.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: March 18, 2014
    Assignee: Merck Patent GmbH
    Inventors: Daniel Cravo, Sophie Hallakou-Bozec, Franck Lepifre
  • Patent number: 8604202
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and B1, B2 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diseases and disorders modulated by AMP agonists. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I).
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: December 10, 2013
    Assignee: Merck Patent GmbH
    Inventors: Daniel Cravo, Franck Lepifre, Sophie Hallakou-Bozec, Christine Charon
  • Patent number: 8563729
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diseases and disorders modulated by AMP agonists. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I).
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: October 22, 2013
    Assignee: Merck Patent GmbH
    Inventors: Daniel Cravo, Franck Lepifre, Sophie Hallakou-Bozec, Christine Charon
  • Patent number: 8486964
    Abstract: The present invention relates to fused pyrrolidino-cyclopropane derivatives according to formulae (I) to (IV) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-?-HSD-1) and the use of such compounds for the treatment and/or prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: July 16, 2013
    Assignee: Merck Patent GmbH
    Inventors: Eric Valeur, Franck Lepifre, Didier Roche, Denis Carniato, Serge Christmann-Franck, Fabien Schmidlin
  • Patent number: 8420643
    Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: April 16, 2013
    Assignee: Critical Outcome Technologies Inc.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Publication number: 20130053401
    Abstract: The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, inflammation, cancer and cardiovascular diseases.
    Type: Application
    Filed: December 28, 2010
    Publication date: February 28, 2013
    Inventors: Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze, Franck Lepifre, Laurent Faveriel, Jean-Denis Durand, Christine Charon
  • Patent number: 8367675
    Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: February 5, 2013
    Assignee: Critical Outcome Technologies Inc.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Publication number: 20120322806
    Abstract: The present invention relates to compounds of formula (I) wherein X, Y, Z, R1, R2, R3 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diabetes, metabolic syndrome, obesity, cancer, inflammation.
    Type: Application
    Filed: August 24, 2012
    Publication date: December 20, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Daniel CRAVO, Sophie HALLAKOU-BOZEC, Franck LEPIFRE
  • Patent number: 8329698
    Abstract: The present invention relates to compounds of formula (I) wherein X, Y, Z, R1, R2, R3 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diabetes, metabolic syndrome, obesity, cancer, inflammation.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: December 11, 2012
    Assignee: Merck Patent Gesellschaft mit Beschränkter Haftung
    Inventors: Daniel Cravo, Sophie Hallakou-Bozec, Franck Lepifre
  • Publication number: 20120077820
    Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Application
    Filed: December 2, 2011
    Publication date: March 29, 2012
    Applicant: CRITICAL OUTCOME TECHNOLOGIES INC.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Publication number: 20110281887
    Abstract: The present invention is directed to methods of use of a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Application
    Filed: July 25, 2011
    Publication date: November 17, 2011
    Applicant: CRITICAL OUTCOME TECHNOLOGIES INC.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre
  • Patent number: 8034815
    Abstract: The present invention is directed to a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: October 11, 2011
    Assignee: Critical Outcome Technologies, Inc.
    Inventors: Wayne R. Danter, Martyn Brown, Franck LePifre